Regenxbio (RGNX) stock and Capricor Therapeutics (CAPR) stock rise as the White House pulls President Trump's pick to lead the FDA. Read more here.
Capricor Therapeutics’ FDA decision date for its resubmitted DMD application shifts from Aug. 22 to Nov. Click here to read an analysis of CAPR stock now.
Capricor Therapeutics (CAPR) stock gained after JonesTrading upgrades the biopharma ahead of a potential U.S. nod for its lead asset, Deramiocel. Read more here.
Capricor is rated Sell. FDA concerns put deramiocel approval odds at 10%-15%, with a new trial likely and over 50% downside. See more on CAPR here.
Capricor Therapeutics Inc (CAPR) reported no Q3 2026 revenue but ended the quarter with approximately $198.5 million in cash and securities as it awaits a November 22, 2026 PDUFA date for Deramiocel.
Capricor Therapeutics (NASDAQ:CAPR) presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration. Company
Capricor Therapeutics (CAPR) shares top-line HOPE-3 extension data for Deramiocel in DMD ahead of its Nov 22 FDA PDUFA date.
Capricor falls 10% despite positive deramiocel HOPE-3 OLE data for DMD. Read more here.
Capricor’s Phase 3 HOPE-3 open-label extension data shows significant improvement in upper limb decline, but H.C. Wainwright said it did not remove the statistical uncertainty from the original trial.
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ca
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy.
Capricor (CAPR) spikes on new deramiocel HOPE-3 24-month Duchenne data ahead of Nov.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Capricor Therapeutics is back in focus after fresh analyst work led to sharply revised price targets, with some models now pointing to fair value estimates as high as US$27.00 from US$4.38. These shifts reflect a wide spread in analyst opinion as investors weigh the extended FDA action date for deramiocel, the mixed advisory committee outcome, and new upper limb function data that some research views as important. Read on to see what is driving the competing narratives around Capricor...
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Compan
Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.
This is the newest page. Registered accounts read further back.